MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy

News & Library

HomeNews & Library
HomeNews & Library

Biotechnologie 2020: „Bench to bedside“

MYR Pharmaceuticals GmbH: Kampf gegen Hepatitis

Eine case study in Plattform Life Sciences, Ausgabe September 2020 (in German). More...


Press releases

September 17, 2020 - MYR Pharmaceuticals launches HEPCLUDEX® in Germany, France and Austria. More...


Scientific Publications

MYR Pharma's scientific founders and collaborators have published numerous papers in top peer reviewed journals describing Myrcludex B mechanism of action and the results of preclinical and clinical development. Myrcludex B has been highlighted in many recent review articles as one of the leading drugs for the treatment of HBV and HDV. More...